Pulmonary Oedema-Therapeutic Targets.

Area of Science:

• Cardiology
• Pulmonary Medicine
• Critical Care Medicine

Background:

• Pulmonary oedema (PO) is a critical manifestation of acute heart failure (AHF), characterized by pulmonary congestion.
• Pathogenesis was traditionally linked to Starling forces, but recent evidence highlights active endothelial and alveolar signaling.
• PO is a medical emergency necessitating urgent, individualized treatment based on hemodynamic status.

Purpose of the Study:

• To review the current understanding of pulmonary oedema (PO) pathogenesis and treatment in acute heart failure (AHF).
• To emphasize the need for evidence-based therapeutic strategies for PO management.
• To identify gaps in current treatments and suggest directions for future pharmacotherapy research.

Main Methods:

• Review of recent studies on PO formation, resolution, and treatment in acute heart failure (AHF).
• Analysis of the limitations of conventional intravenous (IV) therapies for PO.
• Identification of the need for novel pharmacotherapies.

Main Results:

• While most patients improve with conventional IV therapies, treatment remains largely opinion-based due to limited evidence.
• Current PO treatments do not offer simultaneous benefits in symptomatic relief, hemodynamic improvement, survival, and end-organ protection.
• Active endothelial and alveolar signaling play critical roles in PO development and resolution.

Conclusions:

• Pulmonary oedema (PO) management in acute heart failure (AHF) requires urgent, tailored interventions.
• There is a significant lack of robust evidence guiding PO therapy, with conventional treatments showing limitations.
• Future research must focus on developing innovative pharmacotherapies that address both congestion relief and end-organ protection in PO.